Endocrinology and Metabolism Sub-division, Developmental Origins of Health and Disease Division, School of Medicine, University of Southampton, Southampton, UK.
Clin Endocrinol (Oxf). 2010 Apr;72(4):520-6. doi: 10.1111/j.1365-2265.2009.03668.x. Epub 2009 Jul 24.
Growth Hormone is abused by athletes for its lipolytic and anabolic properties. Its use is prohibited by the World Anti-Doping Agency. The GH-2000 project developed a methodology to detect its abuse using the concentrations of two GH-dependent biomarkers, IGF-I and type 3 procollagen (P-III-P). The sensitivity of this method may be improved by considering intra-individual variability.
The aim of this study was to examine the intra-individual variability of IGF-I, P-III-P and the GH-2000 score.
IGF-I, P-III-P and GH-2000 score were evaluated in four longitudinal studies involving 303 elite and 78 amateur athletes. Samples were collected over a period of up to 12 months from a total of 238 men and 143 women aged between 17 and 53 years (mean 24.2).
The four studies showed good agreement with no apparent difference in within-individual variation between amateur and elite athletes. The intra-individual variability for IGF-I ranged between 14-16% while the variability for P-III-P was 7-18%. No athlete tested positive for growth hormone during any of the studies. The overall mean intra-individual variability of the GH-2000 score was less than 0.6 units in all studies.
The high stability of marker levels suggests that concentrations are largely genetically determined. Adopting a test based on the concept of an athlete's 'passport' or 'profiling' would take advantage of this and most likely increase the sensitivity of the test. These data also provide strong evidence that a positive test result for GH abuse would not occur as a result of chance variability.
生长激素因其脂解和合成代谢特性而被运动员滥用。世界反兴奋剂机构禁止其使用。GH-2000 项目开发了一种使用两种 GH 依赖性生物标志物 IGF-I 和 3 型前胶原(P-III-P)的浓度来检测其滥用的方法。通过考虑个体内变异性,可以提高这种方法的灵敏度。
本研究旨在检查 IGF-I、P-III-P 和 GH-2000 评分的个体内变异性。
在四项涉及 303 名精英和 78 名业余运动员的纵向研究中评估了 IGF-I、P-III-P 和 GH-2000 评分。从年龄在 17 至 53 岁之间(平均 24.2 岁)的 238 名男性和 143 名女性中,在长达 12 个月的时间内采集了样本。
四项研究均显示出良好的一致性,业余和精英运动员之间个体内变异无明显差异。IGF-I 的个体内变异性在 14-16%之间,而 P-III-P 的变异性为 7-18%。在任何研究中都没有运动员对生长激素检测呈阳性。所有研究中 GH-2000 评分的总体个体内变异性均小于 0.6 个单位。
标志物水平的高度稳定性表明浓度在很大程度上是由遗传决定的。采用基于运动员“护照”或“分析”概念的检测方法将利用这一点,并且很可能提高检测的灵敏度。这些数据还提供了强有力的证据,证明由于偶然变异性,不会出现 GH 滥用的阳性检测结果。